Peter Lawson

Stock Analyst at Barclays

(0)
# 4736
Out of 5,335 analysts
138
Total ratings
31.33%
Success rate
-20.59%
Average return
42 Stocks
Name Action PT Current % Upside Ratings Updated
KPTI Karyopharm Therapeut...
Maintains: Overweight
5 10
4.82 107.47% 3 May 13, 2025
IOVA Iovance Biotherapeut...
Maintains: Overweight
5 4
1.78 124.72% 7 May 12, 2025
XNCR Xencor
Maintains: Underweight
22 6
8.13 -26.2% 2 May 8, 2025
KURA Kura Oncology
Maintains: Overweight
32 11
5.83 88.68% 1 May 2, 2025
ARVN Arvinas
Maintains: Overweight
32 16
6.3 153.97% 8 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
40 15
8.11 84.96% 2 May 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
63 47
46.27 1.58% 4 Apr 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
29 14
8.66 61.66% 7 Apr 23, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
11 3
1.63 84.05% 5 Apr 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
14 3
1.33 125.56% 2 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 4
1.21 230.58% 1 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
25 29
37.03 -21.69% 5 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
54 60
40.05 49.81% 3 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
14 17
2.85 496.49% 5 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
32 33
10.19 223.85% 4 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
5
n/a n/a 4 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
92 66
28.6 130.77% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 8
1.56 412.82% 8 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
75 105
99.61 5.41% 10 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 31
9.74 218.28% 2 Jul 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
13 17
7.44 128.49% 3 Jun 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 13
1.39 835.25% 1 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
9 26
n/a n/a 6 Apr 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 10
1 900% 3 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
27 31
n/a n/a 6 Dec 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
2 1
0.25 300% 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
7 5
1.02 390.2% 4 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
175 50
n/a n/a 2 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
7 4
2.49 40.56% 4 Jul 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
355 365
80.32 354.43% 1 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
46
28.75 60% 2 Oct 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
40
n/a n/a 1 May 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
0.71 4125.35% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
33
n/a n/a 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
65 75
n/a n/a 2 Dec 4, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
49
n/a n/a 1 May 31, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
21
n/a n/a 1 Apr 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
19 5
n/a n/a 4 Apr 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
16 45
37.26 20.77% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
17 45
1.49 2920.13% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
70
0.14 49900% 1 Jul 14, 2017